Calcium antagonists and mortality risk in men and women with hypertension in the Framingham Heart Study

Archives of Internal Medicine

Volumn 158, Issue 17, 1998, Pages 1882-1886

  Abascal, Vivian M ^a,b   Larson, Martin G ^a,b   Evans, Jane C ^a,b   Blohm, Ana T ^a   Poli, Kim ^a   Levy, Daniel ^a,b,c,d  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; DILTIAZEM; FELODIPINE; NICARDIPINE; NIFEDIPINE; VERAPAMIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; CORONARY DISEASE; FEMALE; HUMANS; HYPERTENSION; MALE; MASSACHUSETTS; MIDDLE AGED; RISK;

EID: 0032575908     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.17.1882     Document Type: Article

References (35)

1. Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis. 1974;27:5-24.
2. Rutan GH, Kuller LH, Neaton JD, Wentworth DN, McDonald RH, Smith WM. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 1988;77:504-514.
3. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final results of the Pooling Project. J Chronic Dis. 1978; 31:201-306.
4. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, I: prolonged differences in blood pressure - prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
5. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, II: short-term reduction in blood pressure - overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827-838.
6. Cutler J, Psaty B, MacMahon S, Furberg C. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. 2nd ed. New York, NY: Raven Press; 1995:253-270.
7. Psaty B, Furberg C. Antihypertensive treatment trials: morbidity and mortality. In: Izzo JL, Black HR, eds. Hypertension Primer. Dallas, Tex: American Heart Association; 1993:197-213.
8. Braunwald E. Mechanism of action of calcium channel blocking agents. N Engl J Med. 1982;307:1618-1627.
9. Weiner DA. Calcium channel blockers. Med Clin North Am. 1988;72:83-115.
10. Frishman WH. Current status of calcium channel blockers. Curr Probl Cardiol. 1994;19:637-688.
11. Frishman WH, Stroh JA, Greenberg SM, et al. Calcium channel blockers in systemic hypertension. Med Clin North Am. 1988;72:449-499.
12. Braunwald E, Muller JE, Stone PH. Use of calcium channel blocker agents in the management of ischemic heart disease. Eur Heart J. 1985;6(suppl A):31-36.
13. Yusuf S. Calcium antagonist in coronary artery disease and hypertension. Circulation. 1995;92:1079-1082.
14. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview of the results from randomized clinical trials. BMJ. 1989;229:1187-1192.
15. Glasser SP, Clark PI, Lipicky RJ, Hubbard JM, Yusuf S. Exposing patients with chronic stable exertional angina to placebo periods in drug trials. JAMA. 1991; 265:1550-1554.
16. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.
17. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
18. Pahor M, Guralnick JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ. Long term survival and use of antihypertensive medications in older patients. J Am Geriatr Soc. 1995;43:1191-1197.
19. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation. 1995;92:1068-1073.
20. Kloner RA. Nifedipine in ischemic heart disease. Circulation. 1995;92:1074-1078.
21. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and acute myocardial infarction: a hypothesis formulated but not yet tested. JAMA. 1995;274: 654-655.
22. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci. 1963;107:539-556.
23. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: The Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
24. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
25. Kannel WB, Wolf PA, Garrison RJ. The Framingham Study: an epidemiological investigation of cardiovascular disease, section 34 - some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. In: Framingham Heart Study, 30-Year Follow-up. Bethesda, Md: National Heart, Lung, and Blood Institute; 1987. US Dept of Health and Human Services NIH publication 87-2703:9-19.
26. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984:91-141.
27. SAS Institute Inc. SAS/STAT Software: Changes and Enhancements Through Release 6.11 (The Phreg Procedure). Cary, NC: SAS Institute Inc; 1996:807-884.
28. Yusuf S, Whittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, I: treatment following myocardial infarction. JAMA. 1988;260: 208.
29. Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post-infarction patients. Eur Heart J. 1988;9:8-16.
30. Braun S, Boyko V, Behar S, et al, and the Benzif ibrate Infarction Prevention Study Participants. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol. 1996;28:7-11.
31. Frohlich ED, McLoughlin MJ, Losem CJ, et al. Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol. 1991; 68:1346-1350.
32. Alderman MH, Cohen H, Roque R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet. 1997;349:594-598.
33. Staessen JA, Fagard R, Thijs L, et al, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
34. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens. 1996;9:342-360.
35. Dahlof B, Hansson L, Lindholm LH, et al. STOP-Hypertension 2: a prospective intervention trial of "newer" versus "older" treatment alternatives in old patients with hypertension. Blood Press. 1993;2:136-141.